The market for radioligand therapies is expected to grow significantly in the coming years. This is due to the increasing number of patients who are being diagnosed with cancer, the growing awareness of radioligand therapies, the increasing number of radioligand therapies that are under clinical trials including Novartis (177Lu-PSMA-617, 225Ac.

放射性配体疗法市场预计将在未来几年显著增长。这是由于被诊断患有癌症的患者数量不断增加，放射性配体疗法的认知度提高，以及越来越多的放射性配体疗法正在进行临床试验，包括诺华公司的177Lu-PSMA-617和225Ac等。

‑

‑

PSMA

前列腺特异性膜抗原

‑

‑

617, 177Lu-NNS309, 177Lu-NeoB, AAA614, and ESP359), Curium Pharma (177Lu-PSMA-I&T), Lantheus and Eli Lilly and Company (Lu-PNT2002 and LNTH-1095), Fusion Pharmaceuticals and AstraZeneca (FPI-2265), Clarity Pharmaceuticals (67CU SAR-BBN and 64Cu-SAR-BBN), and others.

617、177Lu-NNS309、177Lu-NeoB、AAA614 和 ESP359），Curium Pharma（177Lu-PSMA-I&T），Lantheus 和 Eli Lilly and Company（Lu-PNT2002 和 LNTH-1095），Fusion Pharmaceuticals 和 AstraZeneca（FPI-2265），Clarity Pharmaceuticals（67CU SAR-BBN 和 64Cu-SAR-BBN），以及其他公司。

LAS VEGAS

拉斯维加斯

,

，

March 12, 2026

2026年3月12日

/PRNewswire/ -- DelveInsight's Radioligand Therapies Market Size, Target Population, Competitive Landscape & Market Forecast report includes a comprehensive understanding of current treatment practices, addressable patient population, which includes top indications such as Breast cancer, Extensive-stage small cell lung cancer (ES-SCLC), Gastroenteropancreatic neuroendocrine tumors (GEP-NETs), Follicular Lymphoma, Glioblastoma multiforme, and others.

/PRNewswire/ -- DelveInsight的放射配体疗法市场规模、目标人群、竞争格局及市场预测报告包含对当前治疗实践、可治疗患者群体的全面理解，其中包括乳腺癌、广泛期小细胞肺癌（ES-SCLC）、胃肠胰神经内分泌肿瘤（GEP-NETs）、滤泡性淋巴瘤、多形性胶质母细胞瘤等主要适应症。

The selected indications are based on approved therapies and ongoing pipeline activity. The report also provides insights into the emerging Radioligand Therapies, market share of individual therapies, and current and forecasted market size from 2020 to 2034, segmented into leading markets (the US, EU4, UK, and Japan)..

所选适应症基于已批准的疗法和正在进行的研发管线活动。报告还提供了新兴放射配体疗法的见解、各疗法的市场份额，以及2020年至2034年当前和预测的市场规模，细分至主要市场（美国、欧盟四国、英国和日本）。

Key Takeaways from the Radioligand Therapies Market Report

放射性配体疗法市场报告的关键要点

The total market size of radioligand therapies in the leading markets is expected to surge significantly by 2034.

预计到2034年，主要市场中的放射配体疗法的总市场规模将大幅增长。

In 2024, the United States holds the largest share of the radioligand therapies market among the 7MM.

2024年，在七大市场中，美国拥有放射配体疗法市场最大的份额。

The report provides the total potential number of patients in the indications, such as

该报告提供了适应症中患者的总潜在数量，例如

Breast cancer, Extensive-stage small cell lung cancer (ES-SCLC), Gastroenteropancreatic neuroendocrine tumors (GEP-NETs), Follicular Lymphoma, Glioblastoma multiforme, and others

乳腺癌、广泛期小细胞肺癌 (ES-SCLC)、胃肠胰神经内分泌肿瘤 (GEP-NETs)、滤泡性淋巴瘤、多形性胶质母细胞瘤等

.

。

In 2024, the 7MM had approximately

2024年，7MM大约有

240,000

240,000

prevalent cases of metastatic prostate cancer.

转移性前列腺癌的普遍病例。

Leading radioligand therapies companies, such as

领先的放射配体治疗公司，如

Novartis, Curium Pharma, Lantheus, Eli Lilly and Company, Fusion Pharmaceuticals, AstraZeneca, Clarity Pharmaceuticals, Bayer, ITM Isotope Technologies, ARTBIO, Convergent Therapeutics, Perspective Therapeutics, PRECIRIX, Ariceum Therapeutic, Nuclidium,

诺华、Curium制药、Lantheus、礼来公司、Fusion制药、阿斯利康、Clarity制药、拜耳、ITM同位素技术、ARTBIO、Convergent治疗学、Perspective治疗学、PRECIRIX、Ariceum治疗学、Nuclidium

and others, are developing novel radioligand therapies that can be available in the radioligand therapies market in the coming years.

和其他公司正在开发新型放射配体疗法，这类疗法可能在未来几年内投放到放射配体疗法市场。

Some of the key radioligand therapies in clinical trials include

一些处于临床试验阶段的关键放射配体疗法包括

177Lu-PSMA-617, 225Ac

177Lu-PSMA-617，225Ac

‑

‑

PSMA

前列腺特异性膜抗原

‑

‑

617, 177Lu-NNS309, 177Lu-NeoB, AAA614, ESP359, 177Lu-PSMA-I&T, Lu-PNT2002, LNTH-1095, FPI-2265, 67CU SAR-BBN, 64Cu-SAR-BBN, 225Ac-PSMA-Trillium, 225Ac-Pelgifatamab, 225Ac-GPC3, ITM-11, 212Pb-NG001, CONV01-α, VMT-α-NET, VMT01, PSV359, CAM-FAP-Ac-225, 225Ac-SSO110, ATT001, NU101, NU201,

617, 177Lu-NNS309, 177Lu-NeoB, AAA614, ESP359, 177Lu-PSMA-I&T, Lu-PNT2002, LNTH-1095, FPI-2265, 67CU SAR-BBN, 64Cu-SAR-BBN, 225Ac-PSMA-Trillium, 225Ac-Pelgifatamab, 225Ac-GPC3, ITM-11, 212Pb-NG001, CONV01-α, VMT-α-NET, VMT01, PSV359, CAM-FAP-Ac-225, 225Ac-SSO110, ATT001, NU101, NU201,

and others.

和其他人。

Discover how big is the radiopharmaceutical or radioligand therapy market @

发现放射性药物或放射性配体治疗市场的规模有多大 @

https://www.delveinsight.com/sample-request/radioligand-therapies-market-forecast

https://www.delveinsight.com/sample-request/radioligand-therapies-market-forecast

Key Factors Driving the Radioligand Therapies Market

推动放射配体疗法市场发展的关键因素

Rising Global Cancer Burden:

全球癌症负担的增加：

The increasing prevalence of cancers such as prostate cancer and neuroendocrine tumors (NETs) is a major factor driving demand for radioligand therapies. These therapies are particularly effective in treating cancers that are difficult to manage with conventional treatments like chemotherapy or external radiation..

癌症（如前列腺癌和神经内分泌肿瘤 (NETs)）发病率的不断上升是推动放射配体疗法需求增长的主要因素。这些疗法在治疗难以通过传统方法（如化疗或外部放疗）控制的癌症时特别有效。

Growing Demand for Targeted and Precision Oncology:

对靶向和精准肿瘤学的需求不断增长：

Radioligand therapies deliver radioactive isotopes directly to tumor cells via specific ligands, enabling highly targeted destruction of cancer cells while minimizing damage to healthy tissue.

放射性配体疗法通过特定的配体将放射性同位素直接递送到肿瘤细胞，从而实现对癌细胞的高度靶向杀伤，同时最大限度地减少对健康组织的损害。

Potential of 177Lu-PNT2002 for Chemotherapy-Naïve mCRPC Patients:

177Lu-PNT2002在化疗初治mCRPC患者中的潜力：

177Lu-PNT2002, a late-stage PSMA-targeted radiotherapeutic candidate, is well-tolerated and holds significant potential in meeting the needs of chemotherapy-naïve mCRPC patients.

177Lu-PNT2002 是一种处于后期阶段的靶向 PSMA 的放射治疗候选药物，具有良好的耐受性，并在满足未接受过化疗的 mCRPC 患者需求方面展现出显著潜力。

Rising Radioligand Therapies Clinical Trial Activities:

放射配体疗法临床试验活动的增加：

The expected launch of radioligand therapies market are expected to change in the coming years due to the launch of emerging therapies such as

预计放射性配体疗法市场将在未来几年因新兴疗法（如某些疗法）的推出而发生变化，

Novartis

诺华

(177Lu-PSMA-617, 225Ac‑PSMA‑617, 177Lu-NNS309, 177Lu-NeoB, AAA614, and ESP359),

(177Lu-PSMA-617、225Ac‑PSMA‑617、177Lu-NNS309、177Lu-NeoB、AAA614 和 ESP359),

Curium Pharma

锔医药公司

(177Lu-PSMA-I&T),

（177Lu-PSMA-I&T），

Lantheus and Eli Lilly and Company

兰索斯和礼来公司

(Lu-PNT2002 and LNTH-1095),

（Lu-PNT2002 和 LNTH-1095），

Fusion Pharmaceuticals and AstraZeneca

Fusion制药公司和阿斯利康

(FPI-2265),

（FPI-2265），

Clarity Pharmaceuticals

清晰制药公司

(67CU SAR-BBN and 64Cu-SAR-BBN),

(67CU SAR-BBN 和 64Cu-SAR-BBN),

Bayer

拜耳

(225Ac-PSMA-Trillium, 225Ac-Pelgifatamab, and 225Ac-GPC3),

（225Ac-PSMA-Trillium、225Ac-Pelgifatamab 和 225Ac-GPC3），

ITM Isotope Technologies

ITM同位素技术

(ITM-11),

(ITM-11)，

ARTBIO

艺术生物

(212Pb-NG001),

(212Pb-NG001),

Convergent Therapeutics

收敛治疗学

(CONV01-α),

（CONV01-α），

Perspective Therapeutics

景观治疗学

(VMT-α-NET, VMT01, and PSV359),

（VMT-α-NET、VMT01 和 PSV359），

PRECIRIX

PRECIRIX

(CAM-FAP-Ac-225),

(CAM-FAP-Ac-225)，

Ariceum Therapeutics

阿里瑟姆治疗公司

(225Ac-SSO110 and ATT001),

(225Ac-SSO110 和 ATT001),

Nuclidium

核素

(NU101 and NU201), and others.

（NU101 和 NU201），以及其他。

According to Sadaf Javed, Manager of Forecasting and Analytics at DelveInsight, the pharmaceutical industry is becoming more interested in targeted radiation therapy as a novel, promising cancer treatment option as a result of the LUTATHERA success story.

据德瓦尔洞察公司预测与分析经理萨达夫·贾韦德称，由于LUTATHERA的成功故事，制药行业对靶向放射治疗作为一种新颖且有前景的癌症治疗选择越来越感兴趣。

Radioligand Therapies Market Analysis

放射性配体治疗市场分析

Radioligand therapy is increasingly recognized as a promising cancer treatment approach. It is mainly used for patients with metastatic neuroendocrine tumors and those with prostate cancer who no longer respond to standard chemotherapy or radiotherapy.

放射性配体疗法正日益被视为一种有前途的癌症治疗方法。它主要用于转移性神经内分泌肿瘤患者以及那些不再对标准化疗或放疗产生反应的前列腺癌患者。

This targeted therapy delivers radioactive agents directly to cancer cells, helping to prolong survival while improving patients' quality of life by reducing harm to surrounding healthy tissues. Several radioligand therapies, including

这种靶向治疗直接将放射性药物递送到癌细胞，有助于延长生存期，同时通过减少对周围健康组织的伤害来改善患者的生活质量。几种放射配体疗法，包括

LUTATHERA, PLUVICTO, XOFIGO, and ZEVALIN

LUTATHERA、PLUVICTO、XOFIGO 和 ZEVALIN

, have already received approval from the US FDA.

，已经获得美国FDA的批准。

Among them, LUTATHERA was the first radioligand therapy approved for the treatment of gastroenteropancreatic neuroendocrine tumors (GEP-NETs) in adults and has recently gained approval for use in pediatric patients as well.

其中，LUTATHERA 是首个获批用于治疗成人胃肠胰神经内分泌肿瘤 (GEP-NETs) 的放射配体疗法，并且最近也获得了用于儿科患者的批准。

The

The

American Society of Clinical Oncology (ASCO)

美国临床肿瘤学会 (ASCO)

has also released a rapid guideline update regarding radiotracers used in PSMA PET imaging to support the selection of patients with mCRPC who may benefit from

还发布了关于PSMA PET成像中使用的放射性示踪剂的快速指南更新，以支持选择可能受益的mCRPC患者

lutetium-177–labeled PSMA-617 radioligand therapy

镥-177标记的PSMA-617放射配体治疗

. Expanding on the original 2014 guideline and its 2022 revision, the update now recommends three radiotracers, including the newly approved flotufolastat F-18, to evaluate patient eligibility.

在2014年原始指南及其2022年修订版的基础上，此次更新现在推荐使用三种放射性示踪剂，包括新批准的氟托福拉stat F-18，以评估患者的资格。

In addition, the

此外，

EANM/SNMMI

欧洲核医学协会/美国核医学与分子影像学会

procedural guidelines assist nuclear medicine specialists in identifying suitable candidates for 177Lu-PSMA radioligand therapy, conducting the treatment in line with best practices, and effectively managing potential adverse effects.

程序指南协助核医学专家确定适合进行177Lu-PSMA放射配体治疗的候选人，按照最佳实践进行治疗，并有效管理潜在的不良反应。

Meanwhile,

同时，

ARTBIO

艺术生物

is advancing a new generation of alpha radioligand therapies (ARTs). The company has relocated its European research laboratories to Oslo Science Park in Oslo, Norway, a move that provides enhanced laboratory infrastructure and access to specialized preclinical expertise in radiotherapeutics.

正在推进新一代的α放射配体疗法 (ART)。该公司已将其欧洲研究实验室迁至挪威奥斯陆的奥斯陆科技园，此举提供了更先进的实验室基础设施，并获得了放射治疗领域专业的临床前专业知识。

This transition is expected to accelerate the development of ARTBIO's ART pipeline and strengthen its radiation-enabled research and development capabilities.

这一转变预计将加速ARTBIO的ART管道的开发，并增强其辐射研究和开发能力。

Learn more about next-generation radiopharmaceutical therapies @

了解有关下一代放射性药物疗法的更多信息 @

Radioligand Therapies Analysis

放射性配体治疗分析

Radioligand Therapies Competitive Landscape

放射性配体治疗的竞争格局

Some of the radioligand therapies under development include

一些正在开发的放射性配体疗法包括

Novartis

诺华

(177Lu-PSMA-617, 225Ac‑PSMA‑617, 177Lu-NNS309, 177Lu-NeoB, AAA614, and ESP359),

(177Lu-PSMA-617、225Ac‑PSMA‑617、177Lu-NNS309、177Lu-NeoB、AAA614 和 ESP359),

Curium Pharma

锔医药公司

(177Lu-PSMA-I&T),

(177Lu-PSMA-I&T),

Lantheus and Eli Lilly and Company

兰索斯和礼来公司

(Lu-PNT2002 and LNTH-1095),

（Lu-PNT2002 和 LNTH-1095），

Fusion Pharmaceuticals and AstraZeneca

融合制药和阿斯利康

(FPI-2265),

（FPI-2265），

Clarity Pharmaceuticals

清晰制药公司

(67CU SAR-BBN and 64Cu-SAR-BBN),

(67CU SAR-BBN 和 64Cu-SAR-BBN),

Bayer

拜耳

(225Ac-PSMA-Trillium, 225Ac-Pelgifatamab, and 225Ac-GPC3),

（225Ac-PSMA-Trillium、225Ac-Pelgifatamab 和 225Ac-GPC3），

ITM Isotope Technologies

ITM同位素技术

(ITM-11),

(ITM-11),

ARTBIO

艺术生物

(212Pb-NG001),

(212Pb-NG001),

Convergent Therapeutics

收敛治疗学

(CONV01-α),

（CONV01-α），

Perspective Therapeutics

视角治疗学

(VMT-α-NET, VMT01, and PSV359),

（VMT-α-NET、VMT01 和 PSV359），

PRECIRIX

PRECIRIX

(CAM-FAP-Ac-225),

(CAM-FAP-Ac-225)，

Ariceum Therapeutics

阿里瑟姆治疗公司

(225Ac-SSO110 and ATT001),

(225Ac-SSO110 和 ATT001),

Nuclidium

核素

(NU101 and NU201), and others.

（NU101 和 NU201），以及其他。

Curium Pharma's 177Lu-PSMA-I&T

Curium Pharma的177Lu-PSMA-I&T

is designed to target the prostate-specific membrane antigen (PSMA), which is present in more than 85% of prostate cancer cells. Due to its high specificity for this antigen, the attached radioisotope selectively binds to and destroys PSMA-expressing tumor cells. The therapy is currently being evaluated in the Phase III ECLIPSE Phase III clinical trial (NCT05204927) for patients with mCRPC..

旨在靶向前列腺特异性膜抗原（PSMA），这种抗原存在于超过85%的前列腺癌细胞中。由于其对该抗原的高特异性，附着的放射性同位素选择性结合并摧毁表达PSMA的肿瘤细胞。该疗法目前正在进行针对mCRPC患者的III期ECLIPSE临床试验（NCT05204927）评估。

Curium Pharma has been advancing its formulation of Lutetium Lu 177 Dotatate for several years, and in July 2024, the company announced the submission of a 505(b)(2) New Drug Application (NDA) for its Lutetium Lu 177 Dotatate Injection.

Curium Pharma 多年来一直在推进其 Lutetium Lu 177 Dotatate 的配方，并于 2024 年 7 月宣布提交了其 Lutetium Lu 177 Dotatate 注射液的 505(b)(2) 新药申请 (NDA)。

Eli Lilly and Company/Point BioPharma's PNT2002

礼来公司/Point BioPharma的PNT2002

is another small-molecule PSMA-targeted radioligand therapy based on 177Lu for the treatment of mCRPC. It combines the PSMA-targeting ligand PSMA-I&T with the beta-emitting radioisotope no-carrier-added 177Lu. Lu‑PNT2002 is currently being studied in a Phase III clinical trial assessing its superiority over the standard of care in pre-chemotherapy mCRPC patients who have progressed after treatment with one androgen receptor pathway inhibitor.

是另一种基于177Lu的小分子PSMA靶向放射配体疗法，用于治疗mCRPC。它将PSMA靶向配体PSMA-I&T与无载体添加的β发射放射性同位素177Lu结合。Lu‑PNT2002目前正在一项III期临床试验中进行研究，评估其在先前接受过一种雄激素受体通路抑制剂治疗后进展的化疗前mCRPC患者中的优越性是否优于标准治疗。

In December 2023, Eli Lilly and Company announced the completion of its acquisition of POINT Biopharma..

2023年12月，礼来公司宣布完成对POINT Biopharma的收购。

LNTH‑1095, also developed by Lantheus, is a PSMA-targeted small-molecule radioligand therapy intended for the treatment of mCRPC. The therapy links the PSMA-targeting ligand LNTH-1095 with a beta-emitting radioisotope and is currently being investigated in a Phase II trial for metastatic prostate cancer.

LNTH‑1095也是由Lantheus开发的一种靶向PSMA的小分子放射配体疗法，旨在治疗mCRPC。该疗法将靶向PSMA的配体LNTH-1095与发射β射线的放射性同位素结合，目前正在进行一项针对转移性前列腺癌的II期临床试验。

The company presented efficacy data for both Lu-PNT2002 and LNTH-1095 at the ESMO Oncology Congress 2024 held in September 2024..

公司在2024年9月举行的2024年欧洲肿瘤内科学会（ESMO）大会上展示了Lu-PNT2002和LNTH-1095的有效性数据。

Meanwhile,

同时，

Fusion Pharmaceuticals

融合制药公司

is advancing its lead candidate

正在推进其领先候选者

FPI

浮动点数指数（FPI）

‑

‑

2265

2265

, which evaluates 225Ac-PSMA-I&T, a small molecule targeting PSMA expressed in prostate cancer cells. This alpha-emitting radiopharmaceutical is currently being studied in the TATCIST trial and the AlphaBreak trial. At present, BAMF Health is assessing FPI-2265 in collaboration with AstraZeneca and Fusion Pharmaceuticals..

，评估225Ac-PSMA-I&T，这是一种靶向前列腺癌细胞中表达的PSMA的小分子。这种发射α粒子的放射性药物目前正在TATCIST试验和AlphaBreak试验中进行研究。目前，BAMF Health正与阿斯利康和Fusion Pharmaceuticals合作评估FPI-2265。

177Lu-edotreotide

177Lu-edotreotide

is ITM's proprietary synthetic targeted radiotherapeutic investigational drug being developed to treat gastroenteropancreatic neuroendocrine tumors (GEP-NETs). The U.S. FDA has assigned a Prescription Drug User Fee Act (PDUFA) target decision date of August 28, 2026.

是ITM公司正在开发的用于治疗胃肠道胰腺神经内分泌肿瘤（GEP-NETs）的专有合成靶向放射治疗研究药物。美国FDA已指定《处方药使用者费用法案》（PDUFA）的目标决定日期为2026年8月28日。

Convergent Therapeutics' CONV01-α (Ac-225 rosopatamab tetraxetan)

康维吉恩特治疗公司的CONV01-α（Ac-225罗索帕单抗四乙酸）

is a proprietary, best-in-class radioantibody labeled with actinium-225 that has demonstrated encouraging efficacy and safety across several Phase 1/2 clinical studies in patients with prostate cancer. Patient enrollment for the CONVERGE-01 trial is currently in progress, while additional studies are being planned..

是一种专有的、同类最佳的放射性抗体，标记有锕-225，在前列腺癌患者的多项1/2期临床研究中已显示出令人鼓舞的疗效和安全性。CONVERGE-01试验的患者招募目前正在进展中，同时正在计划更多的研究。

The anticipated launch of these emerging therapies are poised to transform the radioligand therapies market landscape in the coming years. As these cutting-edge therapies continue to mature and gain regulatory approval, they are expected to reshape the radioligand therapies market landscape, offering new standards of care and unlocking opportunities for medical innovation and economic growth..

这些新兴疗法的预期推出将在未来几年内改变放射性配体疗法市场的格局。随着这些尖端疗法不断成熟并获得监管批准，它们有望重塑放射性配体疗法市场，提供新的治疗标准，并为医疗创新和经济增长带来机遇。

To know more about which companies are developing radioligand therapies, visit @

要了解更多正在开发放射配体疗法的公司，请访问 @

Radioligand Therapies Treatment

放射性配体治疗

Recent Developments in the Radioligand Therapies Market

放射配体疗法市场的最新进展

In

在

March 2026, ITM Isotope Technologies Munich SE

2026年3月，慕尼黑ITM同位素技术公司

presented post-hoc subgroup analyses from the Phase 3 ITM-11 COMPETE trial involving patients with Grade 1 or Grade 2 somatostatin receptor (SSTR)-positive gastroenteropancreatic neuroendocrine tumors (GEP-NETs).

展示了来自3期ITM-11 COMPETE试验的事后亚组分析，涉及1级或2级生长抑素受体（SSTR）阳性的胃肠道胰腺神经内分泌肿瘤（GEP-NETs）患者。

In

在

March 2026, Lantheus Holdings, Inc.

2026年3月，兰特卢斯控股有限公司

announced that the FDA had granted tentative approval to its Abbreviated New Drug Application (ANDA) for Lutetium Lu 177 Dotatate (PNT2003), a radioequivalent version of LUTATHERA (lutetium Lu 177 dotatate).

宣布FDA已对其镥177 Dotatate（PNT2003）的简略新药申请（ANDA）给予暂时批准，该药物是LUTATHERA（镥177 dotatate）的放射性等效版本。

In

在

January 2026, Zonsen PepLib Biotech Inc.

2026年1月，尊森PepLib生物科技公司

announced a global licensing agreement with Novartis for an undisclosed peptide-based candidate in the radioligand therapy (RLT) space. As part of the deal, Novartis has secured exclusive worldwide rights and will oversee the asset's development and commercialization.

宣布与诺华达成了一项全球许可协议，涉及一款未公开的基于肽的放射配体治疗（RLT）候选药物。根据协议，诺华获得了该药物的全球独家权利，并将负责其开发和商业化。

In

在

January 2026, Swiss Rockets AG and Alloy Therapeutics, Inc.

2026年1月，瑞士火箭公司和合金治疗公司。

entered into a Master Research Agreement (MRA) to initiate a multi-target partnership focused on the discovery and development of next-generation radioligand therapeutics (RLTs) for oncology. The collaboration will be carried out through Swiss Rockets' radiotherapeutics subsidiary, Torpedo Pharmaceuticals AG..

签署了一份主研究协议 (MRA)，以启动一项多目标合作，专注于发现和开发用于肿瘤学的下一代放射配体治疗药物 (RLT)。该合作将通过瑞士火箭公司的放射治疗子公司 Torpedo Pharmaceuticals AG 进行。

In

在

January 2026, ARTBIO, Inc.

2026年1月，ARTBIO公司

began dosing two U.S.-based patient cohorts in the ARTISAN Phase 1 trial of AB001, an alpha radioligand therapy designed to treat metastatic castration-resistant prostate cancer (mCRPC), enrolling patients with and without prior Lu177-PSMA targeted therapy exposure.

开始在ARTISAN第一阶段试验中对两个基于美国的患者队列进行AB001的剂量施用，这是一种旨在治疗转移性去势抵抗性前列腺癌（mCRPC）的α放射配体疗法，纳入了有和无先前Lu177-PSMA靶向治疗暴露的患者。

In

在

November 2025, ITM Isotope Technologies Munich SE

2025年11月，慕尼黑ITM同位素技术公司

announced that the U.S. Food and Drug Administration had completed its filing review and accepted the company's New Drug Application (NDA) for n.c.a. 177Lu-edotreotide, also referred to as ITM-11.

宣布美国食品药品监督管理局已完成其档案审查，并接受了该公司关于n.c.a. 177Lu-edotreotide（也称为ITM-11）的新药申请（NDA）。

What are Radioligand Therapies?

什么是放射配体疗法？

Radioligand therapies (RLTs) are a class of targeted cancer treatments that combine a radioactive isotope with a ligand, a molecule designed to specifically bind to receptors or proteins that are highly expressed on tumor cells. Once administered, the ligand guides the radioactive payload directly to cancer cells, allowing the radiation to destroy malignant tissue while minimizing damage to surrounding healthy cells.

放射性配体疗法（RLTs）是一类靶向癌症治疗药物，它将放射性同位素与一种配体结合，这种配体是一种专门设计用于与在肿瘤细胞上高表达的受体或蛋白质特异性结合的分子。一旦施用，配体会引导放射性物质直接到达癌细胞，使辐射能够摧毁恶性组织，同时尽量减少对周围健康细胞的损害。

This targeted approach improves therapeutic precision and reduces systemic toxicity compared to conventional radiation or chemotherapy. Radioligand therapies have shown significant promise in the treatment of several cancers, particularly prostate and neuroendocrine tumors. By integrating molecular targeting with radiation therapy, RLTs represent an emerging and rapidly evolving modality in precision oncology..

这种有针对性的方法与传统的放疗或化疗相比，提高了治疗的精确性并减少了全身毒性。放射配体疗法在多种癌症的治疗中显示出显著的前景，特别是前列腺癌和神经内分泌肿瘤。通过将分子靶向与放射治疗相结合，放射配体疗法代表了精准肿瘤学中一种新兴且快速发展的治疗模式。

Radioligand Therapies Epidemiology Segmentation

放射性配体疗法流行病学细分

The radioligand therapies market report is a comprehensive and specialized analysis, offering in-depth epidemiological insights for the study period 2020–2034 across the leading markets. About

放射性配体治疗市场报告是一份全面且专业的分析，提供了2020-2034年研究期间主要市场的深入流行病学见解。关于

80%

80%

of SCLC cases were 65 or older, reflecting the advanced median age of diagnosis, 71 years. The radioligand therapies target patient pool is segmented into:

小细胞肺癌病例中65岁及以上的患者占多数，反映了诊断时的中位年龄为71岁。放射性配体疗法针对的患者群体分为：

Total Cases of Selected Indications for Radioligand Therapies

所选放射性配体治疗适应症的总病例数

Total Eligible Patient Pool for Radioligand Therapies in Selected Indications

特定适应症中放射配体疗法的总合格患者群体

Total Treated Cases in Selected Indications for Radioligand Therapies

选定适应症的放射配体治疗总病例数

Radioligand Therapies Report Metrics

放射性配体疗法报告指标

Details

详细信息

Study Period

学习期

2020–2034

2020–2034

Radioligand Therapies Report Coverage

放射配体疗法报告覆盖范围

7MM [The United States, the EU-4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan]

七国集团 [美国、欧盟四国（德国、法国、意大利和西班牙）、英国和日本]

Key Indications Covered in the Report

报告中涵盖的关键适应症

Breast cancer, Extensive-stage small cell lung cancer (ES-SCLC), Gastroenteropancreatic neuroendocrine tumors (GEP-NETs), Follicular Lymphoma, Glioblastoma multiforme, and others

乳腺癌、广泛期小细胞肺癌 (ES-SCLC)、胃肠胰神经内分泌肿瘤 (GEP-NETs)、滤泡性淋巴瘤、多形性胶质母细胞瘤等

Radioligand Therapies Target Patient Pool Segmentation

放射性配体疗法目标患者群体细分

Total Cases of Selected Indications for Radioligand Therapies, Total Eligible Patient Pool for Radioligand Therapies in Selected Indications, and Total Treated Cases in Selected Indications for Radioligand Therapies

放射性配体疗法选定适应症的总病例数、选定适应症中放射性配体疗法的总合格患者池、以及选定适应症中放射性配体疗法的总治疗病例数

Key Radioligand Therapies Companies

关键放射配体治疗公司

Novartis, Curium Pharma, Lantheus, Eli Lilly and Company, Fusion Pharmaceuticals, AstraZeneca, Clarity Pharmaceuticals, Bayer, ITM Isotope Technologies, ARTBIO, Convergent Therapeutics, Perspective Therapeutics, PRECIRIX, Ariceum Therapeutic, Nuclidium, and others

诺华、Curium制药、Lantheus、礼来公司、Fusion制药、阿斯利康、Clarity制药、拜耳、ITM同位素技术、ARTBIO、Convergent治疗学、Perspective治疗学、PRECIRIX、Ariceum治疗学、Nuclidium等

Key Radioligand Therapies

关键放射配体疗法

177Lu-PSMA-617, 225Ac‑PSMA‑617, 177Lu-NNS309, 177Lu-NeoB, AAA614, ESP359, 177Lu-PSMA-I&T, Lu-PNT2002, LNTH-1095, FPI-2265, 67CU SAR-BBN, 64Cu-SAR-BBN, 225Ac-PSMA-Trillium, 225Ac-Pelgifatamab, 225Ac-GPC3, ITM-11, 212Pb-NG001, CONV01-α, VMT-α-NET, VMT01, PSV359, CAM-FAP-Ac-225, 225Ac-SSO110, ATT001, NU101, NU201, LUTATHERA, XOFIGO, PLUVICTO, ZEVALIN, and others.

177Lu-PSMA-617、225Ac‑PSMA‑617、177Lu-NNS309、177Lu-NeoB、AAA614、ESP359、177Lu-PSMA-I&T、Lu-PNT2002、LNTH-1095、FPI-2265、67CU SAR-BBN、64Cu-SAR-BBN、225Ac-PSMA-Trillium、225Ac-Pelgifatamab、225Ac-GPC3、ITM-11、212Pb-NG001、CONV01-α、VMT-α-NET、VMT01、PSV359、CAM-FAP-Ac-225、225Ac-SSO110、ATT001、NU101、NU201、LUTATHERA、XOFIGO、PLUVICTO、ZEVALIN等。

Scope of the

范围

Radioligand Therapies

放射性配体疗法

Market Report

市场报告

Radioligand Therapies Therapeutic Assessment:

放射性配体疗法治疗评估：

Radioligand Therapies' current marketed and emerging therapies

放射性配体疗法的当前已上市和新兴疗法

Radioligand Therapies

放射配体疗法

Market Dynamics:

市场动态：

Conjoint Analysis of Emerging Radioligand Therapies Drugs

新兴放射配体治疗药物的联合分析

Competitive Intelligence Analysis:

竞争情报分析：

SWOT analysis and Market entry strategies

SWOT分析与市场进入策略

Unmet Needs, KOL's views, Analyst's views, Radioligand Therapies Market Access and Reimbursement

未满足的需求、关键意见领袖的观点、分析师的观点、放射性配体疗法的市场准入和报销

Discover upcoming radioligand therapies in oncology @

发现肿瘤学中即将到来的放射配体疗法 @

Radioligand Therapies Clinical Trials

放射性配体治疗临床试验

Table of Contents

目录

1

1

Radioligand Therapies Market Key Insights

放射性配体疗法市场关键洞察

2

2

Radioligand Therapies Market Report Introduction

放射性配体治疗市场报告介绍

3

3

Key Highlights from Radioligand Therapies Market Report

放射配体疗法市场报告的关键亮点

4

4

Executive Summary of Radioligand Therapies

放射配体疗法的执行摘要

5

5

Key Events

关键事件

6

6

Epidemiology and Market Forecast Methodology

流行病学与市场预测方法论

7

7

Radioligand Therapies Market Overview at a Glance in the 7MM

七大市场放射性配体治疗市场概况一览

7.1

7.1

Market Share (%) Distribution by Therapies in 2024

2024年各疗法市场份额（%）分布

7.2

7.2

Market Share (%) Distribution by Therapies in 2034

2034年各疗法市场份额（%）分布

7.3

7.3

Market Share (%) Distribution by Indication in 2024

2024年按适应症划分的市场份额（%）分布

7.4

7.4

Market Share (%) Distribution by Indication in 2034

2034年按适应症划分的市场份额（%）分布

8

8

Background and Overview

背景与概述

8.1

8.1

Introduction

介绍

8.2

8.2

Treatment

治疗

9

9

Target Patient Pool

目标患者群体

9.1

9.1

Key Findings

主要发现

9.2

9.2

Assumptions and Rationale: 7MM

假设与理由：7MM

9.3

9.3

Epidemiology Scenario in the 7MM

七大市场（7MM）的流行病学情景

9.3.1

9.3.1

Total Cases in Selected Indications for Radioligand Therapies in the 7MM

7MM中放射配体疗法在选定适应症中的总病例数

9.3.2

9.3.2

Total Eligible Patient Pool of Selected Indications for Radioligand Therapies in the 7MM

7MM中放射配体疗法选定适应症的总合格患者池

9.3.3

9.3.3

Total Treated Cases in Selected Indications for Radioligand Therapies in the 7MM

7MM中放射配体疗法在选定适应症中的总治疗病例数

10

10

Marketed Radioligand Therapies

上市的放射配体疗法

10.1

10.1

Key Competitors

主要竞争对手

10.2

10.2

LUTATHERA (lutetium LU 177 dotatate): Novartis

LUTATHERA（镥177 dotatate）：诺华

10.2.1

10.2.1

Product description

产品描述

10.2.2

10.2.2

Regulatory milestones

监管里程碑

10.2.3

10.2.3

Other developmental activities

其他开发活动

10.2.4

10.2.4

Safety and efficacy

安全性与有效性

10.2.5

10.2.5

Product profile

产品概况

10.3

10.3

PLUVICTO (lutetium lu-177 vipivotide tetraxetan): Novartis

PLUVICTO（镥-177 维匹沃肽四乙酸）：诺华

List to be continued in the report

报告中待续的列表

11

11

Emerging Radioligand Therapies

新兴放射配体疗法

11.1

11.1

Key Competitors

主要竞争对手

11.2

11.2

Lu-177-PSMA-I&T: Curium Pharma

Lu-177-PSMA-I&T：Curium Pharma

11.2.1

11.2.1

Product description

产品描述

11.2.2

11.2.2

Other developmental activity

其他开发活动

11.2.3

11.2.3

Clinical developmental activities

临床发育活动

11.2.3.1

11.2.3.1

Clinical trial information

临床试验信息

11.2.4

11.2.4

Safety and efficacy

安全性与有效性

11.3

11.3

Lu-PNT2002: Lantheus and Eli Lilly and Company/Point BioPharma

Lu-PNT2002：Lantheus 和 Eli Lilly and Company/Point BioPharma

11.4

11.4

FPI-2265: Fusion/Astrazeneca

FPI-2265：Fusion/阿斯利康

List to be continued in the report

报告中待续的列表

12

12

Radioligand Therapies Market: 7MM Analysis

放射性配体疗法市场：7MM分析

12.1

12.1

Key Findings

主要发现

12.2

12.2

Radioligand Therapies Market Outlook

放射性配体治疗市场展望

12.3

12.3

Conjoint Analysis

联合分析

12.4

12.4

Key Radioligand Therapies Market Forecast Assumptions

关键放射配体治疗市场预测假设

12.5

12.5

Radioligand Therapies Market Size by Indications in the 7MM

7MM中按适应症划分的放射性配体治疗市场大小

12.6

12.6

Radioligand Therapies Market Size by Therapies in the 7MM

七大市场（7MM）中按疗法划分的放射性配体治疗市场规模

12.7

12.7

United States Radioligand Therapies Market Size

美国放射配体疗法市场规模

12.7.1

12.7.1

Market Size by Indications in the US

美国各适应症市场规模

12.7.2

12.7.2

Market Size by Therapies in the US

美国按疗法划分的市场规模

12.8

12.8

EU4 and the UK Radioligand Therapies Market Size

欧盟四国和英国放射性配体治疗市场规模

12.9

12.9

Japan Radioligand Therapies Market Size

日本放射性配体疗法市场规模

13

13

Radioligand Therapies Market Unmet Needs

放射性配体疗法市场未满足的需求

14

14

Radioligand Therapies Market SWOT Analysis

放射性配体疗法市场SWOT分析

15

15

KOL Views on Radioligand Therapies

关键意见领袖对放射配体疗法的看法

16

16

Radioligand Therapies Market Access and Reimbursement

放射性配体疗法市场准入与报销

17

17

Bibliography

参考文献

18

18

Radioligand Therapies Market Report Methodology

放射性配体治疗市场报告方法论

Related Reports

相关报告

PSMA-targeted Therapy Market

PSMA靶向治疗市场

PSMA-targeted Therapy Market Size, Target Population, Competitive Landscape & Market Forecast

PSMA靶向治疗市场规模、目标人群、竞争格局与市场预测

–

–

2034

2034

report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, market share of the individual therapies, and key PSMA-targeted therapy companies, including

报告深入介绍了该疾病的理解、历史和预测流行病学、各疗法的市场份额以及关键的PSMA靶向治疗公司，包括

Lantheus, Telix Pharmaceuticals, Novartis

兰泰乌斯、特利克斯制药、诺华

, and others.

，以及其他。

Prostate Cancer Market

前列腺癌市场

Prostate Cancer Market Insights, Epidemiology, and Market Forecast – 2034

前列腺癌市场洞察、流行病学和市场预测 - 2034年

report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key prostate cancer companies, including

报告深入介绍了该疾病、历史和预测的流行病学，以及市场趋势、市场驱动因素、市场障碍和关键的前列腺癌公司，包括

Sanofi, AstraZeneca, Astellas Pharma, Bayer, Novartis, Curium, Merck, Orion, Janssen Pharmaceutical, Pfizer, Exelixis, Ipsen Pharma, Takeda, AB Science, Lantheus, Eli Lilly, POINT Biopharma, Telix Pharmaceuticals, Tavanta Therapeutics, Jiangsu Hengrui Pharmaceuticals, Kangpu Biopharmaceuticals, Fusion Pharma, Merus, Bristol-Myers Squibb, Syntrix Pharmaceuticals, Promontory Therapeutics, Xencor, Taiho Pharmaceutical, Madison Vaccines, MacroGenics, Zenith Epigenetics, Modra Pharmaceuticals, Arvinas, Laekna Therapeutics, Blue Earth Therapeutics, Oncternal Therapeutics, Essa Pharma, Clarity Pharmaceuticals, BioNTech, DualityBio, Daiichi Sankyo, Fortis Therapeutics, ORIC Pharmaceuticals, Amgen,.

赛诺菲、阿斯利康、安斯泰来制药、拜耳、诺华、Curium、默克、奥立龙、杨森制药、辉瑞、Exelixis、益普生制药、武田、AB Science、Lantheus、礼来、POINT Biopharma、Telix Pharmaceuticals、Tavanta Therapeutics、江苏恒瑞医药、康朴生物医药、Fusion Pharma、Merus、百时美施贵宝、Syntrix Pharmaceuticals、Promontory Therapeutics、Xencor、大鹏制药、Madison Vaccines、MacroGenics、Zenith Epigenetics、Modra Pharmaceuticals、Arvinas、来凯医药、Blue Earth Therapeutics、Oncternal Therapeutics、Essa Pharma、Clarity Pharmaceuticals、BioNTech、DualityBio、第一三共、Fortis Therapeutics、ORIC Pharmaceuticals、安进。

and others.

和其他人。

Neuroendocrine Tumors

神经内分泌肿瘤

Market

市场

Neuroendocrine Tumors

神经内分泌肿瘤

Market Insights, Epidemiology, and Market Forecast

市场洞察、流行病学和市场预测

–

–

2034

2034

report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key neuroendocrine tumors companies including

报告深入介绍了该疾病、历史和预测的流行病学，以及市场趋势、市场驱动因素、市场壁垒和主要神经内分泌肿瘤公司，包括

Novartis, Merck, Pfizer, ITM Solucin GMBH, Camurus, Bristol Myers Squibb, Rayzebio, Exelixis, Ipsen, Takeda, Radiomedix, Orano Med, Perspective Therapeutics, Elicera Therapeutics, Chimerix, Enterome, Teclison

诺华、默克、辉瑞、ITM Solucin GMBH、Camurus、百时美施贵宝、Rayzebio、Exelixis、益普生、武田、Radiomedix、Orano Med、Perspective Therapeutics、Elicera Therapeutics、Chimerix、Enterome、Teclison

,

，

and others.

和其他人。

Gastroenteropancreatic Neuroendocrine Tumors Market

胃肠胰神经内分泌肿瘤市场

Gastroenteropancreatic Neuroendocrine Tumors Market Insights, Epidemiology, and Market Forecast – 2034

胃肠胰神经内分泌肿瘤市场洞察、流行病学与市场预测——2034

report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key GEP-NET companies including

报告提供了对疾病、历史和预测流行病学以及市场趋势、市场驱动因素、市场壁垒和主要GEP-NET公司的深入理解，包括

Novartis, Ipsen Biopharmaceuticals, Pfizer, ITM Isotopen Technologien Muenchen, Camurus AB, Hutchison Medipharma Limited, Bristol-Myers Squibb, Eisai Limite, Experior S.L., Tarveda Therapeutics, Roche Pharma A, Exelixis, Merck Sharp & Dohme Corp, Recordati Inc, Eli Lilly and Company, Genentech, Inc., Aveo Oncology Pharmaceuticals, Radiomedix, Orano Med, PharmaMar, Bayer, Trio Medicines,.

诺华、益普生生物制药、辉瑞、慕尼黑ITM同位素技术、Camurus AB、和记黄埔医药有限公司、百时美施贵宝、卫材有限公司、Experior S.L.、Tarveda治疗学、罗氏制药、Exelixis、默克夏普和多姆公司、Recordati公司、礼来公司、基因泰克公司、Aveo肿瘤制药、Radiomedix、Orano Med、PharmaMar、拜耳、Trio医药。

and others.

和其他人。

About

关于

DelveInsight

德莱夫洞察

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.

德尔维洞察（DelveInsight）是一家领先的商业咨询和市场研究公司，专注于生命科学领域。它通过提供全面的端到端解决方案来支持制药公司以提升其业绩。通过我们的订阅平台 PharmDelve，您可以轻松获取所有医疗保健和制药市场研究报告。

.

。

Contact Us

联系我们

Shruti Thakur

Shruti Thakur

[email protected]

电子邮件地址

+14699457679

+14699457679

Logo:

标志：

https://mma.prnewswire.com/media/1082265/3528414/DelveInsight_Logo.jpg

https://mma.prnewswire.com/media/1082265/3528414/DelveInsight_Logo.jpg

SOURCE DelveInsight Business Research, LLP

来源：DelveInsight商业研究公司

21

21

%

%

more press release views with

更多新闻稿浏览量与

Request a Demo

请求演示